HighTower Advisors LLC Purchases 237 Shares of LeMaitre Vascular, Inc. $LMAT

HighTower Advisors LLC lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 4.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,920 shares of the medical instruments supplier’s stock after purchasing an additional 237 shares during the quarter. HighTower Advisors LLC’s holdings in LeMaitre Vascular were worth $497,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Avantax Advisory Services Inc. increased its holdings in shares of LeMaitre Vascular by 1.5% in the first quarter. Avantax Advisory Services Inc. now owns 15,035 shares of the medical instruments supplier’s stock worth $1,261,000 after purchasing an additional 229 shares during the last quarter. Fifth Third Bancorp increased its holdings in shares of LeMaitre Vascular by 2.3% in the first quarter. Fifth Third Bancorp now owns 10,903 shares of the medical instruments supplier’s stock worth $915,000 after purchasing an additional 246 shares during the last quarter. Cetera Investment Advisers increased its holdings in shares of LeMaitre Vascular by 11.5% in the fourth quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier’s stock worth $254,000 after purchasing an additional 284 shares during the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of LeMaitre Vascular in the first quarter worth about $26,000. Finally, US Bancorp DE increased its holdings in shares of LeMaitre Vascular by 36.0% in the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 368 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director John A. Roush sold 6,561 shares of the business’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the transaction, the director owned 2,916 shares in the company, valued at $269,875.80. The trade was a 69.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO George W. Lemaitre sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the transaction, the chief executive officer owned 1,727,003 shares of the company’s stock, valued at $161,492,050.53. This trade represents a 5.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 120,815 shares of company stock worth $11,280,206 over the last three months. 9.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on LMAT. Barrington Research raised LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 target price on the stock in a report on Wednesday, August 6th. Cantor Fitzgerald boosted their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $97.60.

LeMaitre Vascular Trading Up 0.1%

Shares of NASDAQ LMAT opened at $95.36 on Friday. The business’s 50 day moving average is $87.40 and its two-hundred day moving average is $86.33. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The stock has a market capitalization of $2.16 billion, a P/E ratio of 46.29, a PEG ratio of 2.45 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The company had revenue of $63.15 million for the quarter, compared to analysts’ expectations of $62.48 million. During the same period in the previous year, the firm posted $0.52 earnings per share. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular’s payout ratio is 38.83%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.